Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01137396 · ClinicalTrials.gov registry record · Phase 2

Modafinil, Sleep Architecture and Cocaine Relapse

A Phase 2 study, sponsored by Yale University.

Completed
Registry status
Phase 2
Development phase
114
Enrollment target

NCT01137396 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 114 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01137396, a Phase 2 study, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 2
Development phase
114 participants
Enrollment target

Study Summary

The medication modafinil has been shown to reduce cocaine use in some cocaine users. The investigators have shown that modafinil taken in the morning improves sleep in chronic cocaine users. The investigators hypothesize that the beneficial effects of modafinil in reducing cocaine use may be related to specific effects modafinil has on sleep. This study will measure sleep and cocaine use in cocaine dependent persons who are trying to stop using cocaine, and will test the connection between modafinil's effects on sleep and cocaine use.

Interventions

  • BEHAVIORAL Cognitive Behavioral Therapy
  • DRUG Modafinil

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 2010-04
Est. Completion 2015-02
Phase Phase 2

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT01137396

The ClinicalTrials.gov registry entry for NCT01137396 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Cognitive Behavioral Therapy is the first listed.

NCT01137396 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01137396 about?

NCT01137396 is a clinical study titled "Modafinil, Sleep Architecture and Cocaine Relapse". The medication modafinil has been shown to reduce cocaine use in some cocaine users. The investigators have shown that modafinil taken in the morning improves sleep in chronic cocaine users. The investigators hypothesize that the beneficial effects of modafinil in reducing cocaine use may be related...

What is the current status of trial NCT01137396?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2010-04. Estimated completion is 2015-02.

What interventions are being tested in trial NCT01137396?

The interventions under investigation include: Cognitive Behavioral Therapy (BEHAVIORAL), Modafinil (DRUG).

Who is sponsoring clinical trial NCT01137396?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.